Steady-state phamiacokinetics of an extended-regimen oral contraceptive with continuous estrogen

被引:21
作者
DiLiberti, Charles E. [1 ]
O'Leary, Christine M. [1 ]
Hendy, Christopher H. [2 ]
Waters, Donald H. [1 ]
Margolis, Marya B. [1 ]
机构
[1] Teva Pharmaceut Ind Ltd, Horsham, PA 19044 USA
[2] Novum Pharmaceut Res Serv, Houston, TX 77042 USA
关键词
Pharmacokinetics; Extended-regimen oral contraceptive; Levonorgestrel; Ethinyl estradiol; Hormone accumulation; MU-G ETHINYLESTRADIOL; LONG-TERM SAFETY; ETHINYL ESTRADIOL; OPEN-LABEL; IN-PLACE; PHARMACOKINETICS; LEVONORGESTREL; EFFICACY; MULTICENTER; WOMEN;
D O I
10.1016/j.contraception.2010.06.015
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: This study was conducted to evaluate the steady-state blood concentrations and potential accumulation of levonorgestrel (LNG) and ethinyl estradiol (EE) administered for up to 84 days and EE alone for 7 additional days as an extended-regimen 91-day oral contraceptive (OC). Study design: An open-label, single-site study was conducted in 30 healthy female volunteers. Subjects received daily doses of 0.15 mg LNG/0.03 mg EE for 84 consecutive days followed by 0.03 mg EE alone for 7 days. Pharmacokinetic (PK) monitoring was conducted on Days 1, 21, 84 and 91. Results: The observed plasma concentrations of LNG after 84 days and of EE after 84 and 91 days were comparable to the steady-state concentrations observed at 21 days. Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations. Conclusion: This study demonstrated that an extended-regimen OC providing 84 days of LNG/EE and 7 days of EE alone has a PK profile similar to a 28-day conventional OC regimen and does not result in any additional accumulation of these hormones. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 24 条
[1]  
Akin M, 1998, AM J OBSTET GYNECOL, V179, pS2
[2]   Long-term safety of an extended-cycle oral contraceptive (Seasonate): A 2-year multicenter open-label extension trial [J].
Anderson, F. D. ;
Gibbons, William ;
Portman, David .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 195 (01) :92-96
[3]   Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol [J].
Anderson, FD ;
Gibbons, W ;
Portman, D .
CONTRACEPTION, 2006, 73 (03) :229-234
[4]   Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen [J].
Anderson, FD ;
Hait, H ;
Hsiu, J ;
Thompson-Graves, AL ;
Wilborn, WH ;
Willlams, RF .
CONTRACEPTION, 2005, 71 (01) :55-59
[5]   A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[6]   Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo [J].
Anderson, Freedolph D. ;
Feldman, Robert ;
Reape, Kathleen Z. .
CONTRACEPTION, 2008, 77 (02) :91-96
[7]  
[Anonymous], 2010, LYBR CURR US PRESCR
[8]  
[Anonymous], DAT FIL
[9]   Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results [J].
Archer, David F. ;
Jensen, Jeffrey T. ;
Johnson, Julia V. ;
Borisute, Hannah ;
Grubb, Gary S. ;
Constantine, Ginger D. .
CONTRACEPTION, 2006, 74 (06) :439-445
[10]   Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone [J].
Bachmann, G ;
Sulak, PJ ;
Sampson-Landers, C ;
Benda, N ;
Marr, J .
CONTRACEPTION, 2004, 70 (03) :191-198